Antheia, a Menlo Park, CA-based pharmaceutical ingredient producer, raised $17M in funding.
The funding included a non-dilutive two-year challenge settlement as much as $11M by way of the BioMaP Consortium and extra funding from In-Q-Tel, Inc. (IQT), Echo Funding Capital (Echo), and a number of other present traders, together with Viking International Buyers.
The corporate intends to make use of the funds for the manufacturing of essential pharmaceutical components to the U.S. and accelerating its commercialization technique.
Led by CEO Christina Smolke, Antheia is a pharmaceutical ingredient producer. Utilizing its novel whole-cell engineering method, the corporate’s biomanufacturing platform permits the reconstruction of biosynthetic pathways of complexity in yeast cells and the scaling of fermentation processes to industrial ranges. This method permits on-demand, agile, and resilient biomanufacturing of essential pharmaceutical components, changing legacy approaches that can’t help the wants of contemporary healthcare.
FinSMEs
21/07/2024
